Results 201 to 210 of about 8,326 (241)

STOP-CINV Study: Safety and Efficacy of IV Akynzeo® (Fosnetupitant 235 mg and Palonosetron 0.25 mg) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Indian Patients. [PDF]

Cureus
Shukla P, Valame S, Nanda S, Shakya NK, Verma AK, Hanji A, Pednekar A, Bhagat S, Patil S, Petare AU, Bhushan S, Barkate H.   +11 more
europepmc   +1 more source

Predictions of CYP-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions [PDF]

Hall, Stephen D., Harrelson, John, Mao, Jialin, Mohutsky, Michael A., Wrighton, Steve A.   +4 more
core  

Ifosfamide-Induced Encephalopathy in Children and Young Adults: The MD Anderson Cancer Center Experience. [PDF]

Cancers (Basel)
Alqahtani S, Bitar SD, Mireles ME, Corrales-Medina FF, Herzog CE, Slopis J, Daw NC.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aprepitant

Hospital Pharmacy, 2003
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Terri Levien, Danial E. Baker   +2 more
openaire   +1 more source

Aprepitant

Reactions Weekly, 2021
  +5 more sources

Comparisons of aprepitant and ondansetron

American Journal of Health-System Pharmacy, 2007
We are responding to the letter from Cavaretta and Noviasky[1][1] concerning Merck’s two Phase III studies of aprepitant 40 mg p.o. versus ondansetron 4 mg (as the hydrochloride salt) i.v. in the prevention of postoperative nausea and vomiting (PONV).[2][2],[3][3] Prophylactic ondansetron ...
Alexandra, Carides, Theodore, Reiss, Christopher, Lines, Bernadette, McKeon, Pierre, Diemunsch   +4 more
openaire   +2 more sources

Aprepitant for Erlotinib-Induced Pruritus

New England Journal of Medicine, 2010
To the Editor: Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 receptor is substance P.1,2 An increase in the number of neurokinin-1 receptors on keratinocytes has been found in patients with chronic ...
Vincenzi B, Tonini G, Santini D
openaire   +3 more sources

Aprepitant – a novel NK1-receptor antagonist

Expert Opinion on Pharmacotherapy, 2003
Recently, a new class of agents, the substance P antagonists, has heralded a novel approach for the control of emesis. Aprepitant (Emend, Merck & Co., Inc.), the first of this class, was recently approved by the FDA for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV).
Lisa, Patel, Celeste, Lindley
openaire   +2 more sources

Aprepitant/ifosfamide

Reactions Weekly, 2023
openaire   +2 more sources